New cocktail of drugs shows promise for tough lung cancer

NCT ID NCT03819465

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether combining the immunotherapy durvalumab with other experimental drugs (danvatirsen, oleclumab) and/or chemotherapy can safely control stage IV non-small cell lung cancer. About 175 people who have not had prior treatment for metastatic disease will receive different drug combinations. The main goal is to check safety and see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

durvalumab (an immunotherapy) combined with danvatirsen, oleclumab, and/or chemotherapy

What this could lead to

If successful, this could point toward new combination treatments that help control advanced lung cancer for longer.

What could go wrong

This is a very early (Phase 1) trial with only 175 participants, so results may not apply broadly. Side effects from combining multiple drugs are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Show contact details

Locations

Research Site

Iowa City, Iowa, 52242, United States
Research Site

Pittsburgh, Pennsylvania, 15212, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Salzburg, 5020, Austria
Research Site

Vienna, 1140, Austria
Research Site

Edegem, 2650, Belgium
Research Site

Bialystok, 15-027, Poland
Research Site

Bydgoszcz, 85-796, Poland
Research Site

Gdansk, 80-214, Poland
Research Site

Grudziądz, 86-300, Poland
Research Site

Lodz, 90-302, Poland
Research Site

Olsztyn, 10-357, Poland
Research Site

Tomaszów Mazowiecki, 97-200, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Wroclaw, 53-413, Poland
Research Site

Krasnoyarsk, 660133, Russia
Research Site

Moscow, 115478, Russia
Research Site

Saint Petersburg, 191014, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Cheongju-si, 28644, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 110-744, South Korea
Research Site

Barcelona, 08025, Spain
Research Site

Barcelona, 8003, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28041, Spain
Research Site

Seville, 41013, Spain
Research Site

Kaohsiung City, 807, Taiwan
Research Site

Taichung, 402, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 112, Taiwan
Research Site

Taipei, 235, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10700, Thailand
Research Site

Chiang Mai, 50200, Thailand
Research Site

Hat Yai, 90110, Thailand